TargaGenix was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Stony Brook, New York
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.targagenixinc.com
- HQ
- Stony Brook, New York
Targagenix Questions
Targagenix's website is https://www.targagenixinc.com
Targagenix's LinkedIn profile is https://www.linkedin.com/company/targagenix
Targagenix has
2 employees.
View email and phone details for 2
employees at Targagenix.
Targagenix's industry is
Biotechnology Research
Targagenix's top competitors are
Cello Therapeutics, Inc.,
Zucero Therapeutics Ltd,
Ojima Group Alumni,
Wntresearch Ab,
Liquid Biopsy,
Hudson Therapeutics, Us Subsidiary Of Shaperon,
Taragenyx,
Hr Horeca,
Diagenomi Ltd.,
Genome Illustration.
Targagenix's categories are Biotechnology Research
Targagenix's founding year is 2013
